StockWatch: Phase III Data for Pfizer-Partnered Hemophilia A Gene Therapy Lifts Sangamo Shares
Nearly a year since Sangamo Therapeutics (SGMO) stock price plunged below $1 a share, the genetic medicines developer very briefly returned to that benchmark on Friday, two days after joining partner Pfizer (PFE) to report positive Phase III data for their …